secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-045585
Event type: other
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO closes strategic partnership with Nippon Shinyaku for MPS gene therapies
--------------------------------------------------------------------------------

- Partnership closed for development/commercialization of RGX-121 (MPS II) and RGX-111 (MPS I) in US and Asia.
- RGX-121 on track as first gene therapy for MPS II; potential FDA approval as early as late 2025.
- CEO Curran Simpson highlights transformative potential for MPS patient populations.
- No financial terms disclosed in this filing; partnership was previously announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312525045585/0001193125-25-045585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312525045585/d909911d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-045585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer